High-frequency Triazole Resistance Found In Nonculturable *Aspergillus fumigatus* from Lungs of Patients with Chronic Fungal Disease

David W. Denning,1,2 Steven Park,4 Cornelia Lass-Florl,5 Marcin G. Fraczek,2,3 Marie Kirwan,1,2 Robin Gore,2 Jaclyn Smith,2 Ahmed Bueid,2 Caroline B. Moore,3 Paul Bowyer,2 and David S. Perlin2,4

1National Aspergillosis Centre, 2School of Translational Medicine, University of Manchester, Manchester, UK, 3Mycology Reference Centre, Manchester Academic Health Science Centre, University Hospital of South Manchester, Manchester, UK, 4Public Health Research Institute, New Jersey Medical School-UMDNJ, Newark, New Jersey, and 5Department für Hygiene, Mikrobiologie und Sozialmedizin, Medizinische Universität Innsbruck, Innsbruck, Austria

**Background.** Oral triazole therapy is well established for the treatment of invasive (IPA), allergic (ABPA), and chronic pulmonary (CPA) aspergillosis, and is often long-term. Triazole resistance rates are rising internationally. Microbiological diagnosis of aspergillosis is limited by poor culture yield, leading to uncertainty about the frequency of triazole resistance.

**Methods.** Using an ultrasensitive real-time polymerase chain reaction (PCR) assay for *Aspergillus* spp., we assessed respiratory fungal load in bronchoalveolar lavage (BAL) and sputum specimens. In a subset of PCR-positive, culture negative samples, we further amplified the CYP51A gene to detect key single-nucleotide polymorphisms (SNPs) associated with triazole resistance.

**Results.** *Aspergillus* DNA was detected in BAL from normal volunteers (4/11, 36.4%) and patients with culture or microscopy confirmed IPA (21/22, 95%). *Aspergillus* DNA was detected in sputum in 15 of 19 (78.9%) and 30 of 42 (71.4%) patients with ABPA and CPA, compared with 0% and 16.7% by culture, respectively. In culture-negative, PCR-positive samples, we detected triazole-resistance mutations (L98H with tandem repeat [TR] and M220) within the drug target CYP51A in 55.1% of samples. Six of 8 (75%) of those with ABPA and 12 of 24 (50%) with CPA had resistance markers present, some without prior triazole treatment, and in most despite adequate plasma drug concentrations around the time of sampling.

**Conclusions.** The very low organism burdens of fungi causing infection have previously prevented direct culture and detection of antifungal resistance in clinical samples. These findings have major implications for the sustainability of triazoles for human antifungal therapy.

*Aspergillus* spp. cause diseases ranging from invasive pulmonary aspergillosis (IPA) in immunocompromised patients to chronic pulmonary aspergillosis (CPA) and fungal allergic diseases, including allergic bronchopulmonary aspergillosis (ABPA) and increased severity of asthma (severe asthma with fungal sensitization [SAFS]) [1, 2]. Millions of individuals worldwide are affected or at risk; recent estimates indicate approximately 3 million patients with CPA, 3 million with ABPA and over 10 million with SAFS [3]. Exposure to hundreds of *Aspergillus fumigatus* conidia is a universal, daily occurrence. Conidia shift from being anergic to the human immune system [4] to producing the largest number of documented allergens of any other living organism on germination [5].

Antifungal therapy with triazoles is recommended for patients with ABPA, CPA, and IPA [6]. There are three licensed triazole compounds highly active against *Aspergillus* spp.—itraconazole, voriconazole, and posaconazole [7]. However, triazole resistance has emerged...
as an important factor limiting successful clinical outcome. Itraconazole resistance in *A. fumigatus* was detected in isolates from California in the late 1980s. In the US recently, Martínez et al. [8] found *A. fumigatus* itraconazole minimum inhibitory concentration (MIC) \( \geq 8 \, \text{mg/L} \) in 13 of 25 (52%) in 2002–2009, compared with 13 of 126 (10%) in 1987–2001; and in Detroit, 18 of 37 (49%) *A. fumigatus* isolates had elevated MICs to the triazoles in 2009, compared with 11 of 45 (24%) in 2003 [9]. Increasing resistance rates have been found since 2004 in the Netherlands and the UK [10–12], with 20% of patients in Manchester in 2009 having triazole-resistant isolates [12]. Extensive use of azoles in agriculture is the putative culprit [13], with the emergence of resistance during treatment documented [11]. Current methodology for resistance detection requires a positive culture but the high frequency of negative cultures greatly limits our ability to detect it.

Oral triazole therapy is given for years to patients with ABPA, SAFS, and CPA, usually safely and effectively [14–17]. Development of resistance results in loss of control of the disease [11, 18]. In these patients, cultures are often negative, and more sensitive means of establishing the reason for loss of disease control are required. For similar reasons, selecting the correct initial therapy as fast as possible is important for good outcomes in IPA [11, 19] with mortality rates ranging from approximately 40–90% with treatment [20, 21].

Mutations in the CYP51A gene, encoding the azole target protein lanosterol 14\(\alpha\)-demethylase, are responsible for most instances of resistance [10, 11, 22]. Mutations may result in structural alterations to the enzyme [22]. The most important CYP51A gene resistance mutations are at codons 54, 220, and 98, although we and others have reported several other mutations [10–12, 23, 24]. A strong bias toward key mutations conferring azole resistance enables direct molecular detection without first culturing *A. fumigatus*.

**METHODS**

**Processing of Normal Volunteer BAL Samples**

All volunteers gave written informed consent and the study was approved by the local Ethical Review Committee. Each volunteer underwent a standard bronchoscopy and bronchoalveolar lavage (BAL). Up to 25 mL BAL fluid was centrifuged and the pellets subjected to DNA extraction using the MycXtra fungal DNA extraction kit (Mycconostica Ltd). Up to 5 mL was centrifuged for culture and from the resuspended pellet was streaked on two Sabouraud plates and incubated at 30°C and 37°C for 7 days, according to the UK national methodology [25].

**Processing of Invasive Aspergillosis BAL Samples**

All BAL specimens had been collected from at-risk and infected patients as part of a standard diagnostic workup in Innsbruck over 3 years. All samples were processed prospectively in the same way when received in the clinical laboratory, and excess samples stored for retrospective PCR analysis. The criteria for the diagnosis of IPA are consistent with modified European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria [26]. Fungal culture and microscopy of 1–5 mL BAL fluid (volume dependent) followed centrifugation (15,000g, 5 min) and resuspension in 0.5 mL. One drop of resuspended sample was inspected under fluorescent microscopy with Calcofluor. The remainder was plated on 3 fungal media (Sabouraud with chloramphenicol, brain heart infusion, and malt extract) and cultured at 30°C and 37°C. Positive cultures were identified by conventional means. Bacterial culture and gram stain were done with 100–150 \( \mu \text{L} \) of BAL fluid. Residual sample was stored at \(-20°C\) or (usually) \(-80°C\) prior to DNA extraction with the MycXtra fungal DNA extraction kit and real-time PCR. All clinical data were anonymized.

**Aspergillus PCR Assay**

We used the commercially available real-time PCR diagnostic assay MycAssay Aspergillus (Mycconostica) for the detection of *Aspergillus* spp. At least 15 different *Aspergillus* spp. are detected with the assay, including the 5 most frequent pathogenic species, and *Penicillium* spp. It uses molecular beacons and targets an area of the 18S ribosomal RNA (rRNA) genome [29]. An internal control sequence of plant origin was included to detect any PCR inhibitors in the sample. On the Cepheid SmartCycler, the assay limit of blank is a cycle threshold (Ct) of 38 cycles with a target sensitivity of 50 18S copies, approximately 1 genome, given a range of 18S copy number from 37 to 90 copies per *A. fumigatus* genome [30]. The assay is CE-marked with a nonquantitative endpoint but we chose to use it (off-label) in a quantitative manner to assess fungal load.

**Direct Detection of Key Azole Resistance Mutations**

As the quantity of *Aspergillus* DNA was modest in most samples (and absent in the IPA samples), a nested PCR approach was used to obtain maximum sensitivity. We partially amplified the
CYP51A gene in two ∼900 bp fragments. Fragment 1 (876 bp) covered the promoter tandem repeat region to codon 98. The second amplicon (748 bp) covered codons 54 to 266. The amplified products were evaluated in a real-time assay with allele-specific molecular beacon directed at key single-nucleotide polymorphisms (SNPs) linked with azole resistance (G54, L98 + promoter tandem repeat [TR], G138, and M220). All results were confirmed by DNA sequencing. Patients’ notes were reviewed for their antifungal treatment. Resistance data were not used for clinical decision making.

RESULTS

Extraction of Aspergillus DNA from Respiratory Samples
Extraction of sufficient fungal DNA for molecular detection is the most challenging technical aspect of PCR for fungi. The combination of very few fungal cells in a clinical sample and a sturdy cell wall requiring fracture for DNA release is problematic. We utilized an optimized bead-beating approach to break open cells, preceded by a digestion step. Overall, 10% efficiency from unswollen conidia was demonstrated (Supplementary Figure S1).

Detection of Aspergillus DNA in Volunteers with PCR
To better understand Aspergillus burdens in the lungs of healthy individuals, we tested BAL from 11 normal adults who underwent bronchoscopy. Of these, 4 culture-negative samples (36.4%) had detectable signals in the PCR assay (Table 1). No signal was detected in 7 samples (63.6%), of which one grew Penicillium spp. (3 morphologies) and 1 Paecilomyces spp. The positive Ct values ranged from 36.2 to 34.3 (Figure 1), consistent with Aspergillus spp. being present in normal lungs.

PCR in Invasive Pulmonary Aspergillosis
We analyzed 22 samples from patients with IPA with mycological confirmation. Of the 22 samples, 20 (90.9%) had hyphae consistent with Aspergillus spp. visible on microscopy. All 22 (100%) were culture-positive for a filamentous fungus, 10 for A fumigatus, 9 for A terreus, and 2 for Penicillium spp., and 1 grew A niger, Rhizopus oryzae, and Lichtheimia corymbifera (PCR-negative). Five of the patients had proven and 17 probable IPA in the context of typical immunocompromising conditions, including organ transplant (n = 10) and acute leukemia. Using the normal volunteer data as negative controls and a Ct cut-off of 36, the sensitivity was 94%, specificity 91%, positive predictive value 97%, and negative predictive value 83%. Seventeen patients (77.3%) had received some antifungal prophylaxis or therapy. Aspergillus DNA was detected by PCR in 21 (95.5%) samples (Table 1) with Ct values ranging from 20.5 to 33.7 (Figure 1). Both samples that grew Penicillium were PCR-positive. Furthermore, in these 22 samples, the signal strength was generally much stronger than that in the normal volunteers, indicative of a greater load of Aspergillus in IPA than in normal people.

PCR in Chronic and Allergic Aspergillosis
In spontaneously produced sputum from patients with ABPA, SAFS, and CPA, we detected Aspergillus DNA much more frequently than cultures were positive. In the ABPA patients, all cultures were negative despite strongly positive immunoglobulin E (IgE) serology for A fumigatus. Aspergillus DNA was detectable by PCR in 15 of 19 (78.9%) ABPA patients (Table 1), 11 of these samples having strong PCR signals (Figure 1). Among the 42 patients with CPA, all of whom had detectable Aspergillus IgG antibodies and grossly abnormal chest radiographs, 7 (16.7%) had a positive culture for A fumigatus and 30 (71.4%) had Aspergillus DNA detectable by PCR (Table 1). In patients with CPA, stronger PCR signals were generally seen in those with positive cultures.

Direct Detection of Azole Resistance
We selected DNA from the first 25 sputum samples obtained from ABPA and CPA patients that were PCR-positive, culture-negative, as well as 4 culture-positive, PCR-positive samples patients with CPA (Supplementary Table S1). No G54 or M138 mutations were found. Four samples had M220 mutations: 2 were M220K and 2 M220R cyp51A substitutions on sequencing. Twenty-seven of 29 (93.1%) had an L98H mutation, and 16 (55.2%) also had an upstream 34 bp TR, the combination conferring itraconazole and voriconazole resistance [10]. The TR was found without the L98H mutation in two samples. Two samples had a M220R mutation with both the TR and L98H mutation. Of the 4 culture-positive

Table 1. Aspergillus Culture, qPCR, and A fumigatus Resistance Mutation Detection in 4 Study Populations

<table>
<thead>
<tr>
<th></th>
<th>ABPA (n=30)</th>
<th>CPA (n=22)</th>
<th>IPA (n=21)</th>
<th>Normals (n=11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Culture positive for Aspergillus spp.</td>
<td>0/19</td>
<td>7/42 (16.7%)</td>
<td>20/22 (90.9%)</td>
<td>0/11</td>
</tr>
<tr>
<td>Culture positive for A fumigatus</td>
<td>0/19</td>
<td>7/42 (16.7%)</td>
<td>10/22 (45.5%)</td>
<td>0/11</td>
</tr>
<tr>
<td>qPCR positive for Aspergillus spp</td>
<td>15/19 (78.9%)</td>
<td>30/42 (71.4%)</td>
<td>21/22 (95.5%)</td>
<td>4/11 (36.4%)</td>
</tr>
<tr>
<td>A. fumigatus CYP51A mutation detected directly from qPCR-positive sample</td>
<td>6/8 (75%)</td>
<td>12/24 (50%)</td>
<td>NTa</td>
<td>NTa</td>
</tr>
</tbody>
</table>

NOTE. qPCR indicates quantitative polymerase chain reaction; ABPA, allergic bronchopulmonary aspergillosis; CPA, chronic pulmonary aspergillosis; IPA, invasive pulmonary aspergillosis.

a NT indicates not tested (insufficient sample remaining).
samples, 2 yielded susceptible isolates, and in one of these clinical samples, no resistance mutations were detected in the other TR + L98H was detected by molecular screening. One patient’s isolate was azole-resistant (itraconazole MIC >8 mg/L, voriconazole MIC 2.0 mg/L, and posaconazole 0.25 mg/L), but no resistance mutation was found in the corresponding clinical sample from which this isolate was cultured or on sequencing the CYP51A gene from the isolate. The fourth patient isolate was multi-azole–resistant and an M220K mutation was found directly in the clinical sample and confirmed by CYP51A sequencing of the isolate. Overall, 16 of 29 (55.1%) samples had evidence of azole resistance and 2 of 4 (50%) isolates.

Prior and Concurrent Azole Therapy
Of the 28 patients sampled (one CPA was sampled both prior to starting therapy and while on posaconazole), resistance markers were found in 6 of 8 (75%) with ABPA or SAFS, and 10 of 20 (50%) with CPA. The time of sampling and azole exposure could be relevant to finding resistance markers; in Table 2 and Supplementary Table S1, these relationships are shown. Low plasma concentrations were seen in 2 of 7 (29%), 0 of 10, and 2 of 5 (40%) patients taking itraconazole, posaconazole, and voriconazole, respectively, but many had received prior therapy. Overall numbers are too small to draw many conclusions other than prior azole exposure and current therapy at the time.

Figure 1. *Aspergillus* load measured by quantitative polymerase chain reaction (qPCR) in respiratory samples from 3 patient groups and 1 volunteer group. Spontaneously produced sputum in clinic from patients with allergic bronchopulmonary aspergillosis (ABPA) (including one patient with severe asthma with fungal sensitization [SAFS]) and chronic pulmonary aspergillosis (CPA) were split for culture and DNA extraction before qPCR. Ct, cycle threshold.
of sampling does not reliably predict azole resistance marker detection.

**Resistance and Therapeutic Outcome**

Two of three patients who had never received azoles had L98H and TR detected; both were culture-negative. One was treated with itraconazole and died of progressive CPA within 3 months. The other was treated with posaconazole and remained stable over the following 12 months. Three of the 4 patients with the M220 marker detected failed therapy immediately (itraconazole 1, posaconazole 3), and the fourth failed therapy 12 months later. Of the 14 patients with L98H and TR markers only, 3 were un evaluable, 6 had failed itraconazole or voriconazole treatment, and 5 had stabilized or improved on posaconazole (n = 3), itraconazole, or voriconazole. Rescue therapy for those with panazole-resistant infections includes thrice weekly liposomal amphotericin B or six times weekly micafungin or caspofungin, through a Port-A-Cath.

**DISCUSSION**

*Aspergillus* spp. can be detected in sputum samples and lung tissue in 'uninfected' patients by optimized culture in 38–42% of people sampled [31, 32]. Our data showing that 36.3% of normal healthy volunteers have detectable *Aspergillus* spp. DNA in BAL samples clearly indicates that the lungs are not typically sterile from a fungal perspective, in contrast to bacteria. This might be expected from daily inhalation of spores and hyphal fragments [33] from the environment.

Culture-positive rates in confirmed IPA are typically ~30% or less [34–36]. Few culturable conidia or hyphae are present in a typical airway sample from those with disease. In one small study of culture-positive cases, less than 20 colony-forming units (CFUs) were cultured from 75% of patients, most with invasive aspergillosis [37]. In 3 series of CPA patients, cultures were positive in 10 of 18 (56%), 15 of 24 (65%), and 34 of 42 (81%) [16, 17, 38]. In ABPA, rates of culture positivity were 58% if 3 specimens were examined [39] and 60% in another study [40]. In our recent study of SAFS (same laboratory methodology), only 2 of 58 (3.5%) grew *Aspergillus* spp., despite frequent requests [15]. In a recently published study using induced sputum and direct plating onto potato dextrose agar, 7% of normal volunteers and 31–63% of asthmatics grew *A. fumigatus* [41]. Clearly, studies of optimal culture methods and sampling are needed, including the impact of antifungal therapy on yield.

Some laboratories have employed PCR-based detection of *Aspergillus* to improve sensitivity with varying degrees of success [42]. Variability among labs has prompted calls for standardized and validated PCR tests for *Aspergillus* spp. As untreated IPA is 100% fatal without complete resolution of immunosuppression (and usually rapidly so) [20, 21], a key target for a molecular diagnostic assay is the early, sensitive diagnosis of IPA. Almost all prior molecular detection studies have focused on BAL or blood from immunocompromised patients [42, 43] and very few on spontaneously produced sputum. In addition, quantification of the fungal load in the airways with qPCR offers much greater precision and dynamic range, facilitating greatly improved understanding of fungal infectious and allergic syndromes, including the time course of infection.

The rapid identification of azole resistance in culture-negative samples provides compelling evidence that PCR offers a more sensitive methodology than culture for the detection of *Aspergillus* spp. Given that azoles are critical components of antifungal therapy, the emergence of azole resistance will clearly impact clinical outcomes. The high prevalence of resistance markers detected among patients with chronic *Aspergillus* infections in the absence of confirmed cultures has important implications for clinical care. If patients harbor resistant strains, as suggested by this molecular marker data, they would be expected to respond poorly to therapy or would show diminished response if a mixed (susceptible and resistant) population was present. We found response rates to antifungal therapy of <50% [41].

### Table 2. Interrelationship Between Azole Therapy, Sampling Time, and Frequency of Azole Resistance Marker Detected

<table>
<thead>
<tr>
<th>Azole treatment experience</th>
<th>Itra</th>
<th>Vori</th>
<th>Posa</th>
<th>None</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azole naive</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>2/3</td>
<td>2/3</td>
</tr>
<tr>
<td>Itra only</td>
<td>2/5</td>
<td>–</td>
<td>–</td>
<td>4/7</td>
<td>4/7</td>
</tr>
<tr>
<td>Posa only</td>
<td>–</td>
<td>–</td>
<td>1/4</td>
<td>0/1</td>
<td>1/4</td>
</tr>
<tr>
<td>Itra + vori</td>
<td>1/1</td>
<td>2/4</td>
<td>–</td>
<td>5/7</td>
<td>5/7</td>
</tr>
<tr>
<td>Itra + Posa</td>
<td>–</td>
<td>–</td>
<td>1/2</td>
<td>–</td>
<td>1/2</td>
</tr>
<tr>
<td>Itra + vori + posa</td>
<td>–</td>
<td>–</td>
<td>3/5</td>
<td>–</td>
<td>3/5</td>
</tr>
<tr>
<td>Totals</td>
<td>3/6</td>
<td>2/4</td>
<td>5/11</td>
<td>6/8</td>
<td>16/29</td>
</tr>
</tbody>
</table>

**NOTE.** Itra indicates itraconazole; vori, voriconazole; posa, posaconazole. * M220 mutation (n = 4).
in ABPA and CPA. Thus, the molecular resistance data may help explain a long-standing clinical conundrum of modest response rates to azole therapy, despite apparently adequate therapy and favorable immune status. Alternative treatments should be considered when resistance markers are identified. The loss of disease control with the emergence of resistance is most consistent with antifungal activity being mediated directly and not by immunological or steroid-boosting effects [15, 44].

A key consideration is whether the molecular approach to finding or excluding resistance demonstrated here is more comprehensive than culture, or too sensitive. In conventional microbiology, only a single colony is typically selected for comprehensive than culture, or too sensitive. In conventional microbiology, only a single colony is typically selected for susceptibility testing, whereas sampling all the Aspergillus DNA in a clinical specimen allows detection of resistance genotypes present in only a subpopulation of infecting strains. We suspect this is the reason why we have found both a higher frequency of resistance overall and a much higher proportion of L98H mutations than we find in isolates that have grown in culture [11, 12]. Reduced culturability on agar (but not necessarily virulence) of certain resistant strains is also a possible explanation of this disparity. The unexpected finding of multiple mutations in the same sample (but not necessarily the same strain) (M220K and L98H) is novel. Likewise, the dissociation of the TR and L98H has not been described to date. Prospective studies with greater statistical power and careful patient monitoring are required.

Enabling direct detection of resistance using rapid molecular methods greatly facilitates optimal therapy for individual patients. Not only will ineffective therapy be avoided, but alternative strategies utilizing combination therapy become directly testable, with microbiological endpoints, instead of relying on imperfect clinical and surrogate biomarker endpoints, as is currently the case. However, translation of the finding of a specific cyp51A mutation into a treatment decision requires additional work for all second-generation triazoles, as our understanding of cross-resistance is currently limited. Furthermore, not all resistance is mediated by cyp51A mutations [9], so while detection of a key SNP is helpful in detecting resistance (and is more sensitive than culture), a negative screen does not rule out resistance, as demonstrated in one patient in this series. Likewise, new mutations conferring resistance are likely to continue to arise, and might be missed without a sequence-based approach.

Our remarkably high rate of resistance (55.1%) needs confirmation from other groups. Triazole resistance rates in A fumigatus cultures of this magnitude have been seen in 2 US institutions [8, 9], and lower (but highly significant) rates in Europe [12, 13]. The environmental presence of azole-resistant A fumigatus strains has been documented in Europe. Resistant strains have been found in the environment in numerous countries, including Denmark and Belgium; 10 of 570 (1.8%) A fumigatus cells found in the air in Belgium were resistant to itraconazole [45]. Thus, the human lung may be a filter of Aspergilli in the air, and what is found in samples reflects recent exposure, especially in patients who cannot clear this fungus from their respiratory tract. Clearly, rapidly expanding antifungal therapy worldwide will favor persistence of resistant subpopulations.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online (http://www.oxfordjournals.org/our_journals/cid/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Acknowledgments

We are indebted to Chris Harris for sourcing patient clinic notes, and to Sarah Follett, Adrian Moody, and Gillian Morgan at Myconostica for their guidance and support.

Financial support. This work was supported by grants from Myconostica and the National Institute Health Research Translational Research Facility in Respiratory Medicine, and National Institutes of Health grant AI066561 to D.S.P. Saudi Arabia’s Ministry of Health funds A.B. The Chronic Granulomatous Disorder Research Trust partially funds M.K. The work of the Mycology Reference Centre Manchester has been undertaken by the Fungal Research Trust since 1991.

Potential conflicts of interest. D.W.D. holds founder shares in F2G Ltd and Myconostica Ltd, both University of Manchester spin-out companies, and has received grant support from F2G as well as the Fungal Research Trust, the Wellcome Trust, the Moulton Trust, The Medical Research Council, The Chronic Granulomatous Disease Research Trust, the National Institute of Allergy and Infectious Diseases, National Institute of Health Research and the European Union, AstraZeneca, and Basilea. He continues to act as an advisor/consultant to F2G and Myconostica as well as other companies over the last 5 years, including Basilea, Vicuron (now Pfizer), Pfizer, Schering Plough, Nektar, Daiichi, Astellas, Gilead, and York Pharma. He has been paid for talks on behalf of Schering, Astellas, Merck, Dainippon, and Pfizer. C.L.-F. acts as consultant to Pfizer, Astellas, and Schering Plough, and was paid for talks on behalf of Pfizer, Astellas, Schering Plough, Merck, and Gilead. C.R.M. holds a grant from Pfizer and is a shareholder in Myconostica. She has been paid for talks on behalf of Pfizer, P.B., holds grants from the EU, Fungal Research Trust, AstraZeneca, and Alergenica, and is a shareholder in Myconostica. D.S.P. receives support from the US National Institute of Allergy and Infectious Diseases; he has received past support from Pfizer and Merck and participates in expert panels for these companies, and is a shareholder in Myconostica. All other authors report no potential conflicts.

References


